180 related articles for article (PubMed ID: 36644580)
41. CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract][Full Text] [Related]
42. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
43. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
[TBL] [Abstract][Full Text] [Related]
44. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.
Holmström MO; Ahmad SM; Klausen U; Bendtsen SK; Martinenaite E; Riley CH; Svane IM; Kjær L; Skov V; Ellervik C; Pallisgaard N; Hasselbalch HC; Andersen MH
Blood Cancer J; 2019 Jan; 9(2):8. PubMed ID: 30655510
[TBL] [Abstract][Full Text] [Related]
45. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
46. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
47. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
48. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
Abdelghani M; Hammami H; Zidi W; Amouri H; Othmen HBH; Farrah A; Menif S
J Clin Lab Anal; 2022 Aug; 36(8):e24522. PubMed ID: 35754115
[TBL] [Abstract][Full Text] [Related]
49. Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.
Rattarittamrong E; Tantiworawit A; Kumpunya N; Wongtagan O; Tongphung R; Phusua A; Chai-Adisaksopha C; Hantrakool S; Rattanathammethee T; Norasetthada L; Charoenkwan P; Lekawanvijit S
Hematology; 2018 Oct; 23(9):613-619. PubMed ID: 29521158
[TBL] [Abstract][Full Text] [Related]
50. β-Carotene 15,15'-oxygenase inhibits cancer cell stemness and metastasis by regulating differentiation-related miRNAs in human neuroblastoma.
Kim YS; Gong X; Rubin LP; Choi SW; Kim Y
J Nutr Biochem; 2019 Jul; 69():31-43. PubMed ID: 31048207
[TBL] [Abstract][Full Text] [Related]
51. [Silencing Calreticulin Expression Inhibits Invasion Ability of SNK6 Cells in Vitro via Down-Regulating Expression of VEGF and MMP2/9].
Zheng Y; Zhu XP; Li CT; Huang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):433-438. PubMed ID: 30998150
[TBL] [Abstract][Full Text] [Related]
52. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
[TBL] [Abstract][Full Text] [Related]
53. Secreted calreticulin mutants subvert anticancer immunosurveillance.
Liu P; Zhao L; Kroemer G; Kepp O
Oncoimmunology; 2020; 9(1):1708126. PubMed ID: 32002304
[TBL] [Abstract][Full Text] [Related]
54. Calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma.
Harada K; Takenawa T; Ferdous T; Kuramitsu Y; Ueyama Y
Oncol Lett; 2017 Jun; 13(6):4857-4862. PubMed ID: 28599487
[TBL] [Abstract][Full Text] [Related]
55. Dexamethasone-Mediated Upregulation of Calreticulin Inhibits Primary Human Glioblastoma Dispersal Ex Vivo.
Nair M; Romero J; Mahtabfar A; Meleis AM; Foty RA; Corbett SA
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29443896
[TBL] [Abstract][Full Text] [Related]
56. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
Araki M; Komatsu N
Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
[TBL] [Abstract][Full Text] [Related]
57. The role of calreticulin mutations in myeloproliferative neoplasms.
Araki M; Komatsu N
Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
[TBL] [Abstract][Full Text] [Related]
58. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
Kepp O; Liu P; Zhao L; Plo I; Kroemer G
Oncoimmunology; 2020 Jul; 9(1):1792037. PubMed ID: 32923154
[TBL] [Abstract][Full Text] [Related]
59. The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.
Belčič Mikič T; Pajič T; Zver S; Sever M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806036
[No Abstract] [Full Text] [Related]
60. Support for down-tuning of the calreticulin gene in the process of human evolution.
Esmaeilzadeh-Gharehdaghi E; Banan M; Farashi S; Mirabzadeh A; Farokhashtiani T; Hosseinkhani S; Heidari A; Najmabadi H; Ohadi M
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1770-3. PubMed ID: 21723904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]